Evidence map›Paper›PMID 41526667›Full record

ArticleNPJ precision oncology2026

Prospective implementation of an aqueous humor liquid biopsy platform informs clinical diagnosis and management of retinoblastoma and other intraocular lesions.

Laura A T Kagami, Eirini Christodoulou, Venkata Yellapantula, Nerea Goni, David N Buckley, Brianne Brown, Dolores Estrine, Cindy Fong, Rima Jubran, Dejerianne Ostrow and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Laura A T Kagami *Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA. lkagami@chla.usc.edu.
Eirini Christodoulou *Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Venkata YellapantulaCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Nerea GoniDivision of Ophthalmology, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
David N BuckleyCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Brianne BrownDivision of Ophthalmology, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Dolores EstrineCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Cindy FongCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Rima JubranCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Dejerianne OstrowCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Mark ReidDivision of Ophthalmology, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Rachana ShahCancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Miao SunCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Dong XuCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Liya XuDivision of Ophthalmology, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Jaclyn A BiegelCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Jesse L BerryDivision of Ophthalmology, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.

Funding

Validation of an aqueous humor liquid biopsy for molecular prognostication and monitoring of children with retinoblastoma.R01CA282759 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI Jesse L Berry · 2023 to 2026
$2.2M
Development of a surrogate liquid biopsy from the aqueous humor in retinoblastoma eyes.K08CA232344 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI BERRY, JESSE L · 2018 to 2022
$1.1M
Alex's Lemonade Stand Foundation and Northwestern Mutual POST Program Grant Award 1299693Alex's Lemonade Stand Foundation Grant 23-27881NCI NIH HHS K08 CA232344NCI NIH HHS R01 CA282759NCI NIH HHS R01CA282759
6 · The paper itself

Abstract

LBSeq4Kids is a clinically validated liquid biopsy platform combining low passage whole genome sequencing (LP-WGS) for copy number alterations (CNAs) and a custom cancer targeted sequencing panel (TSP) to detect sequence variants in cell-free DNA from the aqueous humor (AH) of the eye, cerebrospinal fluid, and plasma. We present LBSeq4Kids results from a prospective cohort of 60 ocular oncology patients, including 41 with retinoblastoma (RB),13 with non-malignant RB simulating lesions and six with other intraocular malignancies. Ninety-four percent of baseline RB samples obtained at diagnosis were positive for CNAs by LP-WGS and 83% were positive for pathogenic variants by TSP analysis. All samples obtained at clinical recurrence were positive for ctDNA whereas none of the eyes in remission had a positive finding. The presence of CNAs detected by serial sampling in patients being treated for RB was correlated with clinical disease status. None of the patients with RB-simulating lesions had a positive finding by LP-WGS. The sensitivity of the assay to detect ctDNA in the setting of active RB was 98%. LBSeq4Kids represents a groundbreaking improvement for intraocular malignancies and is highly effective in informing accurate diagnosis, risk stratification, response to therapy, and surveillance.

Identifiers

PMID41526667
PMCPMC12868883

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.